logo

For the Inventor, By the Inventor

Gaithersburg, MD, United States of America

Haodong Li

This inventor holds 60 USPTO granted patents and 3 published patent applications, primarily in Chemokine Antibodies (CPC class 536 ). Top assignees: Human Genome Sciences, Inc., Smithkline Beecham Corporation, The Institute for Genomic Research. Active years: 1996-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Haodong Li. Retrieved from https://idiyas.com/inventor/haodong-li

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 60 

% Patents Active = 66.7

Average Co-Inventor Count = 2.9

ph-index = 12

Forward Citations = 458(Granted Patents)

Forward Citations (Not Self Cited) = 407(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Gaitheresburg, MD (US) (2000 - 2003)
  • Germantown, MD (US) (1996 - 2004)
  • Gaithersburg, MD (US) (1997 - 2010)

Company Filing History:

goldMedal56 out of 676 
 
Human Genome Sciences, Inc.
 patents
silverMedal1 out of 2,198 
 
Smithkline Beecham Corporation
 patents
bronzeMedal1 out of 4 
 
The Institute for Genomic Research
 patents
4. 1 out of 159 
 
Transgene S.a.
 patents
5. 4 out of 834,708 
Other
 patents
where one patent can have more than one assignee

Years Active: 1996-2010

Loading Chart...
Areas of Expertise:
Chemokine Antibodies
MPIF-1
LAI-1
M-CIF
Growth Factor
Polypeptides
Viral Vectors
Stem Cells
Monocyte Inhibitory Factor
Natural Killer Cells
Epidermal Growth Factor
Cystatin F
60 patents (USPTO):Explore Patents
1. 7851596 - Myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptides (2010-12-14),
2. 7419662 - Methods of making chemokine alpha 3 antibodies (2008-09-02),
3. 7393832 - Extracellular/epidermal growth factor like protein (2008-07-01),
4. 7364865 - Antibodies to myeloid progenitor inhibitory factor-1 (MPIF-1) (2008-04-29),
5. 7332302 - Polynucleotides encoding leukocyte adhesion inhibitor-1 (LAI-1) (2008-02-19),
6. 7309780 - Antibodies to natural killer cell activating factor II (2007-12-18),
7. 7198944 - Human chemokine β-9 viral vectors (2007-04-03),
8. 7183081 - Human Ckβ-10 polynucleotides (2007-02-27),
9. 7138498 - Antibodies to MCP-4 (2006-11-21),
10. 7122639 - Chemokine alpha-2 antibodies (2006-10-17),
11. 7097985 - Antibodies to human chemokine beta-9 (2006-08-29),
12. 7078482 - Natural killer cell activating factor II (2006-07-18),
13. 7041460 - Antibodies to monocyte-colony inhibitory factor (M-CIF) (2006-05-09),
14. 7026299 - Connective tissue growth factor-2 (2006-04-11),
15. 6936688 - Human chemokine beta-10 mutant polypeptides (2005-08-30),

Title: The Innovations of Haodong Li: A Pioneer in Chemokine Therapeutics

Introduction: Haodong Li, based in Gaithersburg, MD, has established himself as a significant figure in the field of biomedical innovations, holding an impressive total of 60 patents. His work primarily focuses on chemokine polypeptides and their therapeutic applications, which are groundbreaking in the treatment of various diseases.

Latest Patents: Among his recent innovations, Haodong Li has developed therapeutic compositions and methods involving isolated nucleic acid molecules encoding human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptides. These compositions demonstrate potential in treating a range of conditions including leukemia, tumors, and chronic infections. Additionally, he has disclosed methods for generating human chemokine Alpha-3 polypeptides and procedures for their therapeutic use, along with methods to diagnose related diseases through innovative assays.

Career Highlights: Haodong Li’s extensive career includes notable contributions while working at Human Genome Sciences, Inc. His research has led to advancements in understanding and manipulating chemokines for therapeutic purposes, thus making him a key player in the domain of biomedical research and applied innovations.

Collaborations: Throughout his career, Haodong has collaborated with experts including Mark D. Adams and Steven M. Ruben. These partnerships have likely enriched his work and propelled his research initiatives, leveraging different perspectives and expertise within the field.

Conclusion: With 60 patents to his name, Haodong Li continues to be a driving force in innovations surrounding chemokine therapeutics and diagnostics. His significant contributions provide promising prospects for advancements in treating complex diseases, thereby enhancing healthcare solutions. His work is a testament to the power of innovation in improving human health.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…